CN109311959A - 肽类似物 - Google Patents

肽类似物 Download PDF

Info

Publication number
CN109311959A
CN109311959A CN201780015231.1A CN201780015231A CN109311959A CN 109311959 A CN109311959 A CN 109311959A CN 201780015231 A CN201780015231 A CN 201780015231A CN 109311959 A CN109311959 A CN 109311959A
Authority
CN
China
Prior art keywords
group
acy
acylated
residues
empty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780015231.1A
Other languages
English (en)
Chinese (zh)
Inventor
许晓瑜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adepthera LLC
Original Assignee
Adepthera LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adepthera LLC filed Critical Adepthera LLC
Priority to CN202310002994.XA priority Critical patent/CN116063580A/zh
Publication of CN109311959A publication Critical patent/CN109311959A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57527—Calcitonin gene related peptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
CN201780015231.1A 2016-01-04 2017-01-04 肽类似物 Pending CN109311959A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310002994.XA CN116063580A (zh) 2016-01-04 2017-01-04 肽类似物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662274638P 2016-01-04 2016-01-04
US62/274,638 2016-01-04
PCT/US2017/012171 WO2017120220A1 (en) 2016-01-04 2017-01-04 Peptide analogs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310002994.XA Division CN116063580A (zh) 2016-01-04 2017-01-04 肽类似物

Publications (1)

Publication Number Publication Date
CN109311959A true CN109311959A (zh) 2019-02-05

Family

ID=59274070

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780015231.1A Pending CN109311959A (zh) 2016-01-04 2017-01-04 肽类似物
CN202310002994.XA Pending CN116063580A (zh) 2016-01-04 2017-01-04 肽类似物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310002994.XA Pending CN116063580A (zh) 2016-01-04 2017-01-04 肽类似物

Country Status (6)

Country Link
US (2) US11034745B2 (cg-RX-API-DMAC7.html)
EP (1) EP3400237A4 (cg-RX-API-DMAC7.html)
JP (1) JP7360794B2 (cg-RX-API-DMAC7.html)
CN (2) CN109311959A (cg-RX-API-DMAC7.html)
TW (1) TW201734035A (cg-RX-API-DMAC7.html)
WO (1) WO2017120220A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200353088A1 (en) * 2017-11-06 2020-11-12 Auckland Uniservices Limited Peptide conjugate cgrp receptor antagonists and methods of preparation and uses thereof
US20210332083A1 (en) * 2018-12-12 2021-10-28 The Regents Of The University Of California Netrin-1 Compounds and Compositions Thereof for Treating Pulmonary Hypertension
CN114686427B (zh) * 2022-05-23 2022-07-29 中国人民解放军总医院第一医学中心 一种脾脏调节型b淋巴细胞及其制备方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080020978A1 (en) * 2005-10-21 2008-01-24 Gegg Colin V Jr CGRP peptide antagonists and conjugates
US20130281374A1 (en) * 2006-08-17 2013-10-24 Astrazeneca Pharmaceuticals Lp Dpp-iv resistant gip hybrid polypeptides with selectable properties
CN103458916A (zh) * 2011-04-07 2013-12-18 小利兰·斯坦福大学托管委员会 长效肽类似物
CN104271596A (zh) * 2012-01-26 2015-01-07 克里斯托弗·J·索尔斯 肽激素的降钙素cgrp家族的肽拮抗剂和它们的用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
AU5366296A (en) 1995-03-22 1996-10-08 Trustees Of Boston University Methods for the detection of paracoccidioides
US6440421B1 (en) 1996-04-18 2002-08-27 Auchkland Uniservices Limited Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
IL118003A0 (en) 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
US6268474B1 (en) 1998-04-30 2001-07-31 Creighton University Peptide antagonists of CGRP-receptor superfamily and methods of use
US20090175821A1 (en) 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6965013B2 (en) 2002-11-26 2005-11-15 The Board Of Trustees Of The Leland Stanford Junior University Intermedin and its uses
US20080026995A1 (en) 2003-07-25 2008-01-31 Ac Immune Sa Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
RU2385878C2 (ru) 2004-02-11 2010-04-10 Амилин Фармасьютикалз, Инк. Пептид, обладающий свойствами амилина (варианты), и его применение (варианты)
JP2008507280A (ja) 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
ZA200700359B (en) 2004-07-21 2008-12-31 Ambrx Inc Biosynthetic polypeptides utilizing non-naturally encoded amino acids
CA2580991A1 (en) 2004-10-08 2006-04-20 Amylin Pharmaceuticals, Inc. Amylin family polypeptide-6 (afp-6) analogs and methods of making and using them
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
CA2597649A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
MX2008002028A (es) 2005-08-11 2008-03-27 Amylin Pharmaceuticals Inc Polipeptidos hibridos con propiedades de seleccion.
AU2007227202B2 (en) 2006-03-21 2013-08-22 Amylin Pharmaceuticals, Llc Peptide-peptidase inhibitor conjugates and methods of using same
WO2008022716A2 (en) 2006-08-22 2008-02-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Screening method for gpcr ligands
KR20090060294A (ko) 2006-09-08 2009-06-11 암브룩스, 인코포레이티드 변형된 인간 혈장 폴리펩티드 또는 Fc 스캐폴드 및 그의 용도
US7956035B2 (en) 2007-03-01 2011-06-07 Csl Limited Treatment of endothelial dysfunction in diabetic patients
UA99914C2 (ru) 2007-05-15 2012-10-25 Оцука Фармас'Ютікел Ко., Лтд. Способ применения антагонистов вазопресина со средствами антрациклиновой химиотерапии для снижения кардиотоксичности
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US20130011382A1 (en) * 2010-01-08 2013-01-10 Profibrix Bv Fibrinogen Preparations Enriched In Fibrinogen With An Extended Alpha Chain
US9543468B2 (en) * 2010-10-12 2017-01-10 Alliance For Sustainable Energy, Llc High bandgap III-V alloys for high efficiency optoelectronics
EP3416676B1 (en) 2016-02-09 2021-12-08 Adepthera LLC Dosing and use of long-acting clr/ramp agonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080020978A1 (en) * 2005-10-21 2008-01-24 Gegg Colin V Jr CGRP peptide antagonists and conjugates
US20130281374A1 (en) * 2006-08-17 2013-10-24 Astrazeneca Pharmaceuticals Lp Dpp-iv resistant gip hybrid polypeptides with selectable properties
CN103458916A (zh) * 2011-04-07 2013-12-18 小利兰·斯坦福大学托管委员会 长效肽类似物
CN104271596A (zh) * 2012-01-26 2015-01-07 克里斯托弗·J·索尔斯 肽激素的降钙素cgrp家族的肽拮抗剂和它们的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAMUEL D ROBINSON ET AL.: "Novel peptide antagonists of adrenomedullin and calcitonin gene-related peptide receptors: identification, pharmacological characterization, and interactions with position 74 in receptor activity-modifying protein 1/3", 《J PHARMACOL EXP THER.》 *

Also Published As

Publication number Publication date
US11034745B2 (en) 2021-06-15
US20190010203A1 (en) 2019-01-10
JP7360794B2 (ja) 2023-10-13
CN116063580A (zh) 2023-05-05
US20220340633A1 (en) 2022-10-27
WO2017120220A1 (en) 2017-07-13
EP3400237A1 (en) 2018-11-14
JP2019504119A (ja) 2019-02-14
TW201734035A (zh) 2017-10-01
EP3400237A4 (en) 2020-03-04

Similar Documents

Publication Publication Date Title
US12110318B2 (en) Peptide analogs
KR102440323B1 (ko) 인크레틴 유사체 및 그의 용도
TWI666220B (zh) 醯化升糖素類似物
JP4949844B2 (ja) エリスロポエチン受容体に結合する新規ペプチド
JP6334537B2 (ja) グルカゴン類似体
JP2019112437A (ja) グルカゴン類似体
JP2020045362A (ja) グルカゴン−glp−1−gipトリプルアゴニスト化合物
CN102397558B (zh) Exendin-4类似物的定位聚乙二醇化修饰物及其用途
ES2988026T3 (es) Agonistas del receptor CRF2 y su uso en terapia
TWI763972B (zh) 經修飾之脂質化鬆弛素b鏈胜肽及其醫療用途
EP3570875B1 (en) Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use
JP2000516579A (ja) 腸栄養性glp―2ペプチドのアンタゴニスト
SG186764A1 (en) Glucagon analogues
JP2007204491A (ja) グルカゴン様ペプチド−2アナログ
CN106913865A (zh) 使用白细胞介素‑10治疗疾病和病症的方法
CA2560174A1 (en) Y4 selective receptor agonists for therapeutic interventions
JP2021515759A (ja) コンプスタチン類似体及びその医療用途
WO2023165476A1 (zh) 针对sort1的多肽化合物及其药物偶联物
US20220340633A1 (en) Superagonist polypeptide analogs of adrenomedullin and intermedin peptide hormones
CN114641303A (zh) Npy2受体激动剂
CN107001440A (zh) 稳定化的肾上腺髓质素衍生物及其用途
CN109310779A (zh) 缀合的c1酯酶抑制剂及其用途
TW202438512A (zh) Glp1/gip/npy2受體之三重促效劑
Niida et al. Antiobesity and emetic effects of a short-length peptide YY analog and its PEGylated and alkylated derivatives
JP6005732B2 (ja) 非ペプチド性重合体−インスリン多量体及びその製造方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination